|Day Low/High||0.28 / 0.32|
|52 Wk Low/High||0.14 / 11.65|
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Insys Therapeutics, Inc.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Insys Therapeutics, Inc.
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Insys Therapeutics, Inc.
Shares of Insys Therapeutics INSY tumbled Thursday after the company revealed that it would be reporting fourth quarter earnings later than expected thanks to delays from its audit committee.
Levi & Korsinsky announces it has commenced an investigation of INSYS Therapeutics, Inc.
-- Fourth Quarter 2016 Net Sales Estimated at $54 million --
These heavily shorted stocks could get squeezed higher if they report positive earnings this week.
The most recent short interest data has been released for the 02/28/2017 settlement date, which shows a 2,019,716 share decrease in total short interest for Insys Therapeutics Inc , to 11,726,537, a decrease of 14.69% since 02/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
In trading on Wednesday, shares of Insys Therapeutics Inc crossed above their 200 day moving average of $12.92, changing hands as high as $13.56 per share. Insys Therapeutics Inc shares are currently trading up about 6.7% on the day.
Cannabis stocks are not affected by the volatility in prices during earnings season and instead trade on positive data such as potential FDA approval on their pipeline of drugs.
Investors in Insys Therapeutics Inc saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new March 17th contracts and identified one put and one call contract of particular interest.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.
On December 8, 2016, six former executives of Insys Therapeutics, Inc.
The Canadian marijuana market is poised for growth as the number of registered patients continues grows and as licensed producers find innovative ways to create value for its shareholders.
GW Pharmaceuticals has developed cannabis-based therapies for treating epilepsy and multiple sclerosis.
Jim Cramer finds reasons to like AEP, AMGN, DOW and HEI.
This rally isn't just about Trump, Cramer says. He thinks investors are cheering the economic outlook.
Investors eyeing a purchase of Insys Therapeutics Inc stock, but tentative about paying the going market price of $12.78/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $9 strike, which has a bid at the time of this writing of 95 cents.
Donald Trump was not the only big winner on Election Day. The cannabis industry got a spark as well.
President-elect Trump's vague healthcare policy has put the $3 trillion industry on edge.
The U.S. president elect has said in the past that he favors the legalization of marijuana, and he is unlikely to change his stance significantly.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.